New onset systemic lupus erythematosus after COVID-19 infection: a case report

Ramachandran, Lintu; Dontaraju, Venkata Satish; Troyer, James; Sahota, Jagpal

doi:10.21037/acr-21-55

Cited by 21 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven patients included in our review were diagnosed with SLE, and one with lupus/mixed connective tissue disease (MCTD) overlap [ 30 – 37 ]. Of these eight patients, four presented with lupus nephritis [ 30 , 31 , 33 , 34 ]. Again, a wide age range was noted (22–85 years) with, 75% (6/8) of cases being female.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19

et al. 2023

View full text Add to dashboard Cite

A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The “population” was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and “intervention” as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1 years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7 days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died—one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Cases of SLE after COVID-19 are uncommon. A few SLE adult cases triggered by SARS-CoV-2 infection are also reported in the literature [ 44 , 45 , 46 ]. The presence of SARS-CoV-2 antibodies and the absence of antibodies for other viruses in all reported patients indicates a link between COVID-19 and SLE.…”

Section: Pediatric Sle Onset Following Covid-19mentioning

confidence: 99%

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Lupu

Miron

Gavrilovici

et al. 2023

Viruses

View full text Add to dashboard Cite

Pediatric systemic lupus erythematosus is a chronic autoimmune disorder with a highly variable course and prognosis. It results in functional abnormalities in the immune system due to intrinsic factors and the use of immunosuppressive therapies associated with underlying comorbidities seem to increase the risk of severe COVID-19 and poor outcomes of the disease in pediatric systemic lupus erythematosus (SLE) patients. The aim of this review is to obtain a better understanding of the existing link between this new viral infection and pediatric lupus. We have analyzed the characteristics of newly diagnosed cases of pediatric SLE following COVID-19 which have been reported in the literature and which describe the impact that COVID-19 has on patients already suffering with pediatric SLE.

show abstract

“…In severe COVID-19 extrafollicular B-cell activation strongly correlated with poor disease prognosis and elevated SARS-CoV-2 specific neutralizing antibodies [ 35 ]. A case of post-COVID-19 systemic lupus erythematosus (SLE) with accompanying B-cell activation was reported [ 36 ]. Another study revealed that 83% of patients with Long COVID develop latent autoimmunity and 62% present with polyautoimmunity.…”

Section: Autoimmunity In Covid-19 and Long Covidmentioning

confidence: 99%

Long COVID in autoimmune rheumatic diseases

Fedorchenko

Zimba

2023

Rheumatol Int

View full text Add to dashboard Cite

Consequences of Corona Virus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with various autoimmune and rheumatic manifestations over the past three years. Emerging evidence points to the possibility of Long COVID predisposition in rheumatic patients due to the changes in immune regulatory response. The aim of this article was to overview data on the pathobiology of Long COVID in patients with RDs. Related risk factors, clinical characteristics, and prognosis of Long COVID in RDs were analyzed. Relevant articles were retrieved from Medline/PubMed, Scopus, and Directory of Open Access Journals (DOAJ). Diverse mechanisms of viral persistence, chronic low-grade inflammation, lasting production of autoantibodies, endotheliopathy, vascular complications, and permanent tissue damage have been described in association with Long COVID. Patients with RDs who survive COVID-19 often experience severe complications due to the immune disbalance resulting in multiple organ damage. Regular monitoring and treatment are warranted in view of the accumulating evidence.

show abstract

New onset systemic lupus erythematosus after COVID-19 infection: a case report

Cited by 21 publications

References 12 publications

A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19

A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Long COVID in autoimmune rheumatic diseases

Contact Info

Product

Resources

About